Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 5, 2012, Pages 453-461

  Farag, Youssef M K ^a   Keithy Reddy, Sai Ram ^b   Mittal, Bharati V ^a   Bansal, Vinod ^c   Fareed, Jaweed ^c   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

CD40 ligand; chronic kidney disease; circulating microparticles; erythropoiesis stimulating agents; P selectin; platelet activation

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CREATININE; FERRITIN; GLUCOSE; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ERYTHROPOIESIS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; SMOKING; THROMBOCYTE ACTIVATION; TREATMENT DURATION;

ADULT; AGED; ANEMIA; BLOOD PLATELETS; CD40 LIGAND; CELL-DERIVED MICROPARTICLES; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84871779903     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611431954     Document Type: Article

References (51)

1. Drueke TB, Locatelli F, Clyne N, et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 ; 355 (20). 2071-2084
2. Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 ; 355 (20). 2085-2098
3. Pfeffer MA, Burdmann EA, Chen CY. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 ; 361 (21). 2019-2032
4. Solomon SD, Uno H, Lewis EF. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 ; 363 (12). 1146-1155
5. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 ; 74 (6). 791-798
6. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008 ; 3 (4). 1077-1083
7. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 ; 74 (6). 782-790
8. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, Iron depletion, and Relative Thrombocytosis: A possible explanation for hemoglobin-survival Paradox in Hemodialysis. Am J Kidney Dis. 2008 ; 52 (4). 727-736
9. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR. Managing anemia in dialysis patients: Hemoglobin cycling and overshoot. Kidney Int. 2008 ; 74 (5). 679-683
10. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 ; 59 (3). 538-548
11. Fareed J, Hoppensteadt DA, Bick RL. Management of thrombotic and cardiovascular disorders in the new millenium. Clin Appl Thromb Hemost. 2003 ; 9 (2). 101-108
12. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986 ; 315 (16). 983-989
13. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998 ; 31 (2). 352-358
14. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990 ; 322 (22). 1549-1554
15. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999 ; 100 (6). 614-620
16. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995 ; 92 (7). 1693-1696
17. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996 ; 94 (6). 1239-1246
18. Koyama H, Maeno T, Fukumoto S, et al. Platelet P-Selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation. 2003 ; 108 (5). 524-529
19. Fateh-Moghadam S, Li Z, Ersel S, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol. 2005 ; 25 (6). 1299-1303
20. Ridker PM, Buring JE, Rifai N. Soluble P-Selectin and the risk of future cardiovascular events. Circulation. 2001 ; 103 (4). 491-495
21. Ahmad S, Jeske WP, Ma Q, Walenga JM, Fareed J. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Thromb Res. 2001 ; 102 (2). 143-151
22. Schonbeck U, Libby P. CD40 Signaling and Plaque Instability. Circ Res. 2001 ; 89 (12). 1092-1103
23. Lim HS, Blann AD, Lip GYH. Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004 ; 109 (21). 2524-2528
24. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 ; 391 (6667). 591-594
25. George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986 ; 78 (2). 340-348
26. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 1991 ; 266 (36). 24302-24307
27. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996 ; 93 (2). 229-237
28. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant. 2003 ; 18 (9). 1834-1841
29. Ashman N, Macey MG, Fan SL, Azam U, Yaqoob MM. Increased platelet-monocyte aggregates and cardiovascular disease in end-stage renal failure patients. Nephrol Dial Transplant. 2003 ; 18 (10). 2088-2096
30. Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002 ; 62 (5). 1757-1763
31. Hocher B, Liefeldt L, Quaschning T, et al. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol. 2007 ; 18 (4). 1323-1330
32. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999 ; 45 (12). 2136-2141
33. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004 ; 43 (2). 244-253
34. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998 ; 79 (4). 399-407
35. Rysz J, Majewska E, Stolarek RA, Banach M, Cialkowska-Rysz A, Baj Z. Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol. 2006 ; 26 (5). 437-444
36. Quaknine-Orlando B, Samama CM, Riou B, et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology. 1999 ; 90 (5). 1454-1461
37. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest. 1991 ; 87 (2). 571-580
38. Spahn DR, Cerny V, Coats TJ, et al. Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Crit Care. 2007 ; 11 (1). R17
39. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001 ; 41 (8). 977-983
40. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 1994 ; 86 (2). 347-350
41. Escolar G, Garrido M, Mazzara R, Castillo R, Ordinas A. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion. 1988 ; 28 (5). 406-411
42. Stasko J, Galajda P, Ivankova J, Holly P, Rozborilova E, Kubisz P. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment. Clin Appl Thromb Hemost. 2007 ; 13 (4). 410-415
43. Taskapan H, Senel S, Ulutas O, et al. Platelet activity and serum homocysteine levels in patients with end-stage renal failure with regard to dialysis modality. Ren Fail. 2006 ; 28 (4). 303-308
44. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000 ; 95 (9). 2983-2989
45. Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia?. Lancet. 1998 ; 352 (9127). 566-567
46. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007 ; 21 (3). 157-171
47. Patel TV MB, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients (Accepted). Nephron Clin Pract. 2008 ; 110 (4). c244 - c250
48. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 ; 74 (5). 679-683
49. Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 ; 24 (3). 431-434
50. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 ; 339 (9). 584-590
51. Homoncik M, Sieghart W, Formann E, et al. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy. Am J Gastroenterol. 2006 ; 101 (10). 2275-2282